COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
-
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics présentera un nouvel anticorps monoclonal, first-in-class, agoniste de FPR2 dans la résolution de l’inflammation chronique au Congrès 2026 de l’AAI
OSE Immunotherapeutics annoncera un nouvel anticorps monoclonal agoniste de FPR2 pour traiter l'inflammation chronique au Congrès 2026 de l'AAI -
-
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
OSE Immunotherapeutics to present a novel FPR2 agonist monoclonal antibody aiming to resolve chronic inflammation at the AAI 2026 Meeting in Boston -
-
-
COMMUNIQUÉ DE PRESSE
Helvetia Baloise delivers a strong 2025 performance, increases total dividends and introduces ambitious financial targets for 2028
Helvetia Baloise reports strong 2025 performance: CHF 633.4 million underlying earnings, CHF 7.70 dividend per share, integration progressing as planned, new financial targets for 2028 unveiled -
-
